赵建军, 韩成贤. 吡柔比星预防膀胱癌复发77例[J]. 蚌埠医学院学报, 2011, 36(5): 486-488.
    引用本文: 赵建军, 韩成贤. 吡柔比星预防膀胱癌复发77例[J]. 蚌埠医学院学报, 2011, 36(5): 486-488.
    ZHAO Jian-jun, HAN Cheng-xian. Clinical research of pirarubicin in the prevention of bladder carcinoma: report of 77 cases[J]. Journal of Bengbu Medical College, 2011, 36(5): 486-488.
    Citation: ZHAO Jian-jun, HAN Cheng-xian. Clinical research of pirarubicin in the prevention of bladder carcinoma: report of 77 cases[J]. Journal of Bengbu Medical College, 2011, 36(5): 486-488.

    吡柔比星预防膀胱癌复发77例

    Clinical research of pirarubicin in the prevention of bladder carcinoma: report of 77 cases

    • 摘要: 目的:探讨预防膀胱癌术后复发更有效的方法。方法:术中系统采用吡柔比星液行肿瘤基底及切缘注射,浸泡膀胱和切口,术后膀胱灌注吡柔比星液。结果:随访6~60个月,1、2、3、4、5年复发率分别为18.2%、6.4%、1.3%、1.3%和0.6%,无一例发生切口种植转移及严重并发症。结论:术中、术后应用吡柔比星预防膀胱癌术后复发安全有效。

       

      Abstract: Objective: To investigate the more effective cure for the postoperative recurrence of bladder carcinoma.Methods: Seventy-seven patients were treated with tumor base injection,bladder incisional margin injection,bladder cavity and incision immersion intraoperatively,postoperation with the intravesical instillation of pirarubicin.Results: The follow-up survey was for six months-sixty months.The total recurrence rate is 28.6%,and recurrence rate of 1-5 years is showed apart as 18.2% 6.4% 1.3%,1.3% and 0.6%.Neither incision margin metastasis,nor serious complication was found.Conclusions: The pirarubicin is safe and effective for preventing the postoperative recurrence of bladder carcinoma.

       

    /

    返回文章
    返回